Aptose Biosciences (NASDAQ:APTO) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research report released on Tuesday. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $2.00 target price on shares of Aptose Biosciences in a research report on Tuesday, December 10th.

Aptose Biosciences Stock Up 4.5 %

NASDAQ:APTO opened at $0.24 on Tuesday. The stock has a market cap of $14.17 million, a P/E ratio of -0.08 and a beta of 1.07. The business’s 50-day moving average price is $0.27 and its two-hundred day moving average price is $0.43. Aptose Biosciences has a twelve month low of $0.13 and a twelve month high of $2.60.

Hedge Funds Weigh In On Aptose Biosciences

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp increased its holdings in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 401,750 shares of the biotechnology company’s stock after purchasing an additional 167,282 shares during the period. Sigma Planning Corp owned approximately 2.22% of Aptose Biosciences worth $165,000 as of its most recent SEC filing. 26.62% of the stock is currently owned by institutional investors and hedge funds.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.